Combining Hormone Therapy with Ozempic for Weight Loss at Menopause

Menopause marks a significant transition in a woman’s life, typically occurring between the ages of 45 and 55. This stage of life brings various challenges, particularly where weight management is concerned.

Understanding Weight Gain During Menopause

It is estimated that around 60% to 70% of women gain weight during menopause, a shift that can be attributed to hormonal changes and aging. As estrogen levels decline, women often lose lean muscle mass and tend to gain fat, particularly in the abdominal area.

“Weight gain is a common concern among midlife women,” explained Dr. Regina Castaneda, a postdoctoral research fellow at the Mayo Clinic Florida. “The menopause transition alongside aging contributes significantly to these changes.”

Additionally, symptoms such as hot flashes, night sweats, and mood swings can further complicate weight management efforts, leading to decreased physical activity and an overall decline in metabolic health.

Current Treatment Options

Those looking to manage weight during menopause have several options available, including:

• Menopausal Hormone Therapy (MHT)
• Lifestyle modifications such as diet and exercise
• GLP-1 medications, which include drugs like Ozempic and Mounjaro

A recent study presented at The Menopause Society’s Annual Conference examined the effectiveness of combining MHT with GLP-1 medications for weight loss. The findings suggest that this combination may enhance weight loss results for menopausal women.

Study Insights: Exploring Effects of MHT and GLP-1 Medications

The study analyzed health records of approximately 2,400 women over 45 who were on either semaglutide (found in Ozempic) or tirzepatide (found in Mounjaro), with some participants receiving MHT and others not.

Dr. Castaneda notes, “More women are turning to GLP-1 therapies to manage their weight as they adjust to menopause, but there’s a common perception that hormone therapy can boost these treatments, despite limited existing evidence.” She emphasizes that this study is the largest of its kind and relied on real-world clinical data.

Key Findings: MHT with GLP-1 in Weight Management

Results indicated that those taking semaglutide alongside MHT experienced significantly greater weight loss that was also more sustainable over time.

However, Dr. Castaneda points out that these findings are still preliminary and should generate further investigation. “It is crucial to acknowledge that MHT is primarily prescribed for managing severe menopausal symptoms, rather than as a primary intervention for weight management,” she clarified.

She adds that alleviating menopausal symptoms through hormone therapy can enhance quality of life, which might motivate women to remain engaged in weight-loss strategies, including diet and exercise.

Tirzepatide's Findings and the Need for More Research

In contrast, the results concerning tirzepatide showed that although participants experienced initial weight loss with MHT, the data did not reach statistical significance. Dr. Castaneda suggests two possibilities for this outcome:

1. The higher efficacy of tirzepatide on its own may limit the observable benefits of MHT.
2. The different mechanisms through which semaglutide and tirzepatide act on the body may influence their interactions with estrogen therapy differently, necessitating further exploration.

Emphasizing the Importance of Weight Control

Experts like Dr. Sheryl Ross have pointed out that managing weight gain during menopause is critical, not just for emotional well-being but also for physical health. “Gaining weight during this stage can increase the risk of diseases like diabetes and heart disease,” she stressed, emphasizing that further research is needed to identify the best strategies for long-term weight management in menopausal women.

MHT's Role in Sustainable Weight Loss

Dr. Prudence Hall elaborated on how MHT can support weight loss: “Hormone replacement therapy tackles root causes of midlife weight gain, including estrogen depletion and adrenal issues.”

The loss of estrogen leads to inflammation and fatigue, which can hinder physical activity and contribute to weight increase. Hormonal imbalances can also disrupt metabolic processes, suggesting that treating these imbalances may aid weight control.

In conclusion, combining MHT with GLP-1 medications like semaglutide may support weight loss efforts for menopausal women. This emerging research highlights the importance of a comprehensive approach to managing menopause-related weight gain, emphasizing physical health along with emotional support.